US approves first-ever obstructive sleep apnea drug

US approves first-ever obstructive sleep apnea drug

/ 08:56 AM January 01, 2025

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep apnea medication. 

Zepbound or Tirzepatide is an injectable drug that the company designed as an obesity treatment. 

READ: Scientists may have found the purpose of sleep

Article continues after this advertisement

The Food and Drug Administration, however, approved it for this health condition due to the results of the SURMOUNT-OSA phase 3 clinical trials. 

FEATURED STORIES

How does this sleep apnea treatment work?

The FDA explains that Tirzepatide works by activating receptors of hormones from the intestine. 

Consequently, the drug reduces body weight, which improves obstructive sleep apnea (OSA).

Article continues after this advertisement

The clinical trials show that Zepbound reduced breathing disruptions by 25 to 29 per hour instead of five to six with a placebo.

Article continues after this advertisement

It mitigated symptoms for 50% of participants who undergo PAP or Positive Airway Pressure) and for 42% of non-PAP patients.

Article continues after this advertisement

Moreover, those who took Zepbound lost 18% to 20% or 45 lbs to 50 lbs in body weight. 

Dan Skovronsky, Eli Lilly’s chief scientific officer, lauded the results in a TIME report:

Article continues after this advertisement

“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” Skovronsky said. 

“Obstructive sleep apnea is still poorly diagnosed. But this is a disease that itself carries cardiovascular risk, as does obesity, so it’s great to treat both.”

“We… have proven that when you treat with Tirzepatide, you remove some fat and the airway can stay open,” he added. 

Cleveland Clinic explains obstructive sleep apnea blocks a person’s airway and restricts oxygen flow.

In response, the person’s survival reflex wakes them to resume breathing. 

“Too often, obstructive sleep apnea is brushed off as ‘just snoring’ – but it’s far more than that,” Project Sleep CEO Julie Flygare told Reuters.

Aside from loud sleep, it could cause fatigue, mood changes, insomnia, headaches, and other health complications. 

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TIME says this sleep apnea and obesity treatment showed the potential to mitigate heart failure and kidney disease in Lilly’s other studies.

TOPICS: drug, technology
TAGS: drug, technology

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2025 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.